Keros Therapeutics, Inc.
KROS
$11.58
$0.110.96%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2,027.27% | 4,750.00% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,027.27% | 4,750.00% | -- | -- | -- |
| Cost of Revenue | -31.09% | 44.19% | 24.53% | 23.05% | -436.52% |
| Gross Profit | 34.50% | -43.08% | -24.42% | -22.78% | 437.10% |
| SG&A Expenses | 17.13% | 7.35% | 13.15% | 32.53% | 28.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.81% | 36.40% | 22.11% | 24.95% | 45.80% |
| Operating Income | -14.64% | -35.53% | -22.02% | -24.73% | -45.35% |
| Income Before Tax | -13.62% | -34.27% | -20.67% | -20.42% | -35.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.37% | -34.27% | -20.67% | -20.42% | -35.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.37% | -34.27% | -20.67% | -20.42% | -35.42% |
| EBIT | -14.64% | -35.53% | -22.02% | -24.73% | -45.35% |
| EBITDA | -14.53% | -35.46% | -21.84% | -24.56% | -45.16% |
| EPS Basic | 14.58% | -5.97% | 1.07% | 4.27% | -22.83% |
| Normalized Basic EPS | 15.14% | -5.97% | 1.05% | 4.27% | -22.83% |
| EPS Diluted | 14.58% | -5.99% | 1.07% | 4.27% | -22.83% |
| Normalized Diluted EPS | 15.14% | -5.97% | 1.05% | 4.27% | -22.83% |
| Average Basic Shares Outstanding | 33.89% | 26.70% | 21.96% | 25.79% | 10.25% |
| Average Diluted Shares Outstanding | 33.89% | 26.70% | 21.96% | 25.79% | 10.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
